Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies
Author:
Funder
Pfizer
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Pharmacology,General Medicine,Biotechnology
Link
https://link.springer.com/content/pdf/10.1007/s40259-019-00375-0.pdf
Reference41 articles.
1. Stein EA. What role will proprotein convertase subtilisin/kexin type 9 inhibitors play in hyperlipidemia management? Curr Opin Endocrinol Diabetes Obes. 2016;23:97–105. https://doi.org/10.1097/MED.0000000000000242
2. Scherer DJ, Nelson AJ, Psaltis PJ, Nicholls SJ. Targeting low-density lipoprotein cholesterol with PCSK9 inhibitors. Intern Med J. 2017;47:856–65. https://doi.org/10.1111/imj.13451.
3. Seidah NG, Awan Z, Chrétien M, Mbikay M. PCSK9: a key modulator of cardiovascular health. Circ Res. 2014;114:1022–36. https://doi.org/10.1161/CIRCRESAHA.114.301621.
4. Vincent J. Reducing elevated plasma LDL cholesterol: the central role of the LDL receptor. Clin Pharmacol Ther. 2014;96:3–7. https://doi.org/10.1038/clpt.2014.95.
5. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med. 2006;354:1264–72. https://doi.org/10.1002/humu.20882.
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody;CPT: Pharmacometrics & Systems Pharmacology;2023-11-22
2. Development of a semi-automated MHC-associated peptide proteomics (MAPPs) method using streptavidin bead-based immunoaffinity capture and nano LC-MS/MS to support immunogenicity risk assessment in drug development;Frontiers in Immunology;2023-11-10
3. PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology;Cancers;2023-02-22
4. Interference in a Neutralizing Antibody Assay for Odronextamab, a CD20xCD3 Bispecific mAb, from Prior Rituximab Therapy and Possible Mitigation Strategy;The AAPS Journal;2022-06-21
5. Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition;Naunyn-Schmiedeberg's Archives of Pharmacology;2022-03-21
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3